73 results about "Angiogenin" patented technology

Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and/or angiogenin are described for use in the related methods, for multi-functional health applications.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.

The invention relates to a preparation method of umbilical cord mesenchymal stem cell liquid for beautifying and maintenance, and belongs to the technical field of medical beautifying. The method comprises the following steps of 1, obtaining umbilical cord stem cells; 2, conducting subculture; 3, preparing the umbilical cord stem cell liquid. According to the technical scheme, umbilical cord stemcells can secrete various cell growth factors to provide a good microenvironment for skin epidermal cells, wherein the cell growth factors include the fibroblastoma growth factor, the fibroblast growth factor, the hepatocyte growth factor, the insulin growth factor, angiogenin and the like; the in-vitro proliferation and migration of human keratinocytes can be activated, skin regeneration and skinwound healing are promoted when the factors enter the skin, the maturity of the skin epidermal cells can be promoted, the skin elasticity is improved, the skin is moisturized, wrinkles are eliminated, pigmentation is prevented, and the liquid has a good beautifying effect.

The invention provides a process for the preparation of an angiogenin-enriched fraction from a milk product, the process comprising contacting the milk product with a cation exchange resin and eluting the angiogenin-enriched fraction from the cation exchange resin with a mobile phase. The invention also provides angiogenin-enriched fractions produced by process and food products, neutraceuticals and pharmaceutical comprising such angiogenin.

The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

The present invention provides a nucleotide-angiogenin conjugated element (ABE) for inhibiting rRNA synthesis induced by angiogenin. The length of the described oligonucleotide is 10-150 bp, and its C+T content is 80%-100% of all the oligonucleotides, and it contains 5-30 continuous CT repetitive units. The experiments show that the specific combination of ABE and angiogenin can inhibit the synthesis of rRNA, and the animal experiments also show that ABE can inhibit the growth of human tumor on naked mouse.

The present invention provides a skin-whitening product which contains human angiogenin with effective concentration to inhibit the production of melanose of skin, said effective concentration is 0.000001% to 0.1% of total weight. Said product can be used for removing freckle, black spot, aged-mark, melanotic nevus and dermal abnormal change due to melanosis, and/or can be used for eliminating wrinkles, raising skin elasticity and preventing dermal senility.

The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.02 to 1.6.

The invention uses biology information to reconstruct Ang crystal structure, and construct the 3D structure, and construct the lacunae mutant that the N end lack 5 amino acid and the C end lack 12 amino acid, the reconstructed Ang mutant would be constructed by gene reconstructing and expression technology. The invention supplies a new method for curing tumor.

The present invention includes a method for treating Alzheimer's Disease, the method comprising the steps of: performing or having performed an assay that determines a level of one or more tRNA derived RNA fragments (tRFs), NOP2/Sun RNA methyltransferase 2 (NSun2), or angiogenin, in a biological sample when compared to a comparator sample; and if the patient has an increase in the one or more tRFs, a decrease in NOP2/Sun RNA NSun2 or NSun2 activity, or an increase in angiogenin or angiogenin activity then treating the patient with a NSun2 agonist, a nucleic acid or protein that inhibits or degrades tRFs, or an inhibitor of angiogenin.